In multiple myeloma (Multiple Myeloma, MM)), proteasome inhibitor PIs can trigger pyroptosis of myeloma cells (Myeloma cells) through the mitochondrial BAX/GSDME pathway and improve the therapeutic efficiency of multiple myeloma treatment (129). Here, GSDME is linked to plasma cell myeloma.